文摘
Propensity-based analyses of low risk prostate cancer patients treated across Canada-wide with low dose rate brachytherapy (LDR), stereotactic body radiotherapy (SABR) or external beam radiotherapy (EBRT) are presented. There were no significant differences in biochemical failure before or after matching for SABR versus LDR although prostate-specific antigen (PSA) nadirs were lower after LDR. For the SABR versus EBRT, SABR had a biochemical failure-free survival (BFFS) trend before matching (P = 0.08), which became significant after matching (P < 0.001).